PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5037089

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MORPHOTEK, INC.	06/20/2018

RECEIVING PARTY DATA

Name:	EISAI, INC.
Street Address:	100 TICE BOULEVARD
City:	WOODCLIFF LAKE
State/Country:	NEW JERSEY
Postal Code:	07677

PROPERTY NUMBERS Total: 8

Property Type	Number
Application Number:	60883271
Application Number:	60888405
Application Number:	11969097
Application Number:	13943060
Application Number:	13540330
Application Number:	14515146
Application Number:	15144334
Application Number:	15839403

CORRESPONDENCE DATA

Fax Number: (215)568-3439

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2155683100
Email: assignments@woodcock.com
Correspondent Name: BAKER & HOSTETLER LLP
Address Line 1: 2929 ARCH STREET
Address Line 2: 12TH FLOOR, CIRA CENTRE
Address Line 4: PHILADELPHIA, PENNSYLVANIA 19104

ATTORNEY DOCKET NUMBER:	104018.009000 / MORR-022
NAME OF SUBMITTER:	FAITH A. POORE
SIGNATURE:	/Faith A. Poore/

DATE SIGNED:	07/05/2018

Total Attachments: 23
source=Assignment_executed_Morphotek_to_Eisai#page1.tif
source=Assignment_executed_Morphotek_to_Eisai#page2.tif
source=Assignment_executed_Morphotek_to_Eisai#page3.tif
source=Assignment_executed_Morphotek_to_Eisai#page4.tif
source=Assignment_executed_Morphotek_to_Eisai#page5.tif
source=Assignment_executed_Morphotek_to_Eisai#page6.tif
source=Assignment_executed_Morphotek_to_Eisai#page7.tif
source=Assignment_executed_Morphotek_to_Eisai#page8.tif
source=Assignment_executed_Morphotek_to_Eisai#page9.tif
source=Assignment_executed_Morphotek_to_Eisai#page10.tif
source=Assignment_executed_Morphotek_to_Eisai#page11.tif
source=Assignment_executed_Morphotek_to_Eisai#page12.tif
source=Assignment_executed_Morphotek_to_Eisai#page13.tif
source=Assignment_executed_Morphotek_to_Eisai#page14.tif
source=Assignment_executed_Morphotek_to_Eisai#page15.tif
source=Assignment_executed_Morphotek_to_Eisai#page16.tif
source=Assignment_executed_Morphotek_to_Eisai#page17.tif
source=Assignment_executed_Morphotek_to_Eisai#page18.tif
source=Assignment_executed_Morphotek_to_Eisai#page19.tif
source=Assignment_executed_Morphotek_to_Eisai#page20.tif
source=Assignment_executed_Morphotek_to_Eisai#page21.tif
source=Assignment_executed_Morphotek_to_Eisai#page22.tif
source=Assignment_executed_Morphotek_to_Eisai#page23.tif

ASSIGNMENT

WHEREAS, **Morphotek, Inc.**, hereinafter referred to as the ASSIGNOR, having its principal place of business at **210 Welsh Pool Road, Exton, Pennsylvania 19341** is the owner of certain inventions or improvements for which applications for Letters Patent have been made or for which Letters Patent have been issued, all of which are listed on Attachment A hereto (hereafter Patent Property); and

WHEREAS, **Eisai, Inc.**, hereinafter referred to as the ASSIGNEE, having its principal place of business at **100 Tice Boulevard, Woodcliff Lake, New Jersey 07677**, is desirous of acquiring the entire right, title and interest in and to the said Patent Property in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and intending to be legally bound hereby, ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said Patent Property and any and all continuations, divisions and renewals of and substitutes for said Patent Property and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover damages recoverable for past infringement of the same, and for violations of provisional rights having arisen from any published application(s) for said Patent Property. ASSIGNOR further assigns to and authorizes said ASSIGNEE to file corresponding applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

It is hereby covenanted that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testify in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

Morphotek, Inc.

By: _____
Shuhei Shimizu

Its: Vice President, Business Development,
IP & Alliance Management

Date: 20 June, 2018

****

STATEMENT OF NOTARY PUBLIC

STATE OF Pennsylvania :

: SS

COUNTY OF Chester :

COMMONWEALTH OF PENNSYLVANIA
NOTARIAL SEAL
THOMAS W APPLE
Notary Public
UWCHLAN TWP, CHESTER COUNTY
My Commission Expires Jul 18, 2019

On this 20 day of June, year of 2018, before me personally came the above named **Shuhei Shimizu** to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

_____
Notary Public

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

Eisai, Inc.

By: Maureen A. Bresnahan

Maureen A. Bresnahan

Its: Assistant Secretary

Date: 20 June 2018

****

STATEMENT OF NOTARY PUBLIC

COMMONWEALTH OF PENNSYLVANIA
NOTARIAL SEAL
THOMAS W APPLE
Notary Public
UWCHLAN TWP, CHESTER COUNTY
My Commission Expires Jul 18, 2019

STATE OF Pennsylvania :

: SS

COUNTY OF Chester :

On this 20 day of June, year of 2018, before me personally came the above named **Maureen A. Bresnahan** to me personally known and known to me to be the same individual who executed the foregoing assignment, and who acknowledged to me that execution of the same was of that person's own free will for the use and purposes therein set forth.

John W. Apple

Notary Public

ATTACHMENT A

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-001-U1PC	Patent Cooperation Treaty	PCT/US2000/030588	11/07/2000	Methods For Generating Genetically Altered Antibodies-Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1US	United States	09/707,468 6,808,894	11/07/2000 10/26/2004	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-C1US	United States	10/243,130 7,235,643	09/13/2002 06/26/2007	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity
MORR-001-D1US	United States	10/850,370	05/19/2004	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-D2US	United States	11/746,868 7,671,179	05/10/2007 03/02/2010	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1CA	Canada	2428214 2428214	11/07/2000 02/02/2010	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1EP	European Patent Convention	00977014.0 1345495	11/07/2000 02/25/2009	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1FR	France	1345495	02/25/2009	Methods For Generating Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1DE	German	60041665.8 1345495	02/25/2009	Methods For Generating Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1GB	United Kingdom	1345495	02/25/2009	Methods For Generating Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U1JP	Japan	540568/02	11/07/2000	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-U2PC	Patent Cooperation Treaty	PCT/US2003/028722	09/12/2013	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity
MORR-001-U2AU	Australia	2003272352	09/12/2003	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity
MORR-001-U2CA	Canada	2544124	09/12/2003	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity
MORR-001-U2EP	European Patent Convention	03754530.8	09/12/2003	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-001-U2JP	Japan	536226/04	09/12/2003	Antibodies And Methods For Generating Genetically Altered Antibodies With High Affinity
MORR-001-D1EP	European Patent Convention	08167325.3 2039251	11/07/2008 02/16/2011	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-D1FR	France	2039251	02/16/2011	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-D1DE	Germany	60045652.8 2039251	02/16/2011	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-D1GB	United Kingdom	2039251	02/16/2011	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-001-D1CH	Switzerland	2039251	02/16/2011	Methods For Generating Genetically Altered Antibodies -Producing Cell Lines With Improved Antibody Characteristics
MORR-002-P1US	United States	60/181,929	02/11/2000	Method For Generating Hypermutable Microbes
MORR-002-P2US	United States	60/211,183	06/13/2000	Method For Generating Hypermutable Microbes
MORR-002-U1PC	Patent Cooperation Treaty	PCT/US2001/004339	02/12/2001	A Method For Generating Hypermutable Microbes
MORR-002-U1US	United States	09/780,675 7,026,119	02/12/2001 04/11/2006	A Method For Generating Hypermutable Microbes
MORR-002-C1US	United States	11/930,391 7,892,832	10/31/2007 02/22/2011	Methods For Generating Hypermutable Microbes
MORR-002-D1US	United States	11/360,995 7,695,969	02/24/2006 04/13/2010	Methods For Generating Hypermutable Microbes
MORR-002-U1CA	Canada	2398094 2398094	02/12/2001 01/08/2013	A Method For Generating Hypermutable Microbes
MORR-002-U1EP	European Patent Convention	01907187.7 1268765	02/12/2001 08/13/2008	A Method For Generating Hypermutable Microbes
MORR-002-U1GB	United Kingdom	1268765	08/13/2008	A Method of Generating Hypermutable Microbes
MORR-003-P2US	United States	60/183,333	02/18/2000	Method For Generating Hypermutable Plants
MORR-003-U1PC	Patent Cooperation Treaty	PCT/US2000/035397	12/28/2000	A Method Of Generating Hypermutable Plants

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-003-U1US	United States	09/749,601 6,900,370	12/28/2000 05/31/2005	A Method Of Generating Hypermutable Plants
MORR-003-C1US	United States	11/128,420 7,704,689	05/15/2005 04/27/2010	Method For Generating Hypermutable Plants
MORR-003-D1US	United States	12/728,958 8,110,356	03/22/10 02/07/2012	Method For Generating Hypermutable Plants
MORR-003-U1CA	Canada	2400664 2400664	12/28/2000 03/01/2011	A Method Of Generating Hypermutable Plants
MORR-003-U1EP	European Patent Convention	00989525.1 1282708	12/28/2000 07/02/2008	A Method Of Generating Hypermutable Plants
MORR-003-U1DE	Germany	1282708	07/02/2008	A Method Of Generating Hypermutable Plants
MORR-003-U1FR	France	1282708	07/02/2008	A Method Of Generating Hypermutable Plants
MORR-003-U1GB	United Kingdom	1282708	07/02/2008	A Method Of Generating Hypermutable Plants
MORR-004-P1US	United States	60/184,336	02/23/2000	Method For Generating Hypermutable Yeast
MORR-004-P2US	United States	60/211,088	06/13/2000	Method For Generating Hypermutable Yeast
MORR-004-U1PC	Patent Cooperation Treaty	PCT/US2001/005447	02/20/2001	Methods For Generating Hypermutable Yeast
MORR-004-U1US	United States	09/788,657 6,656,736	02/21/2001 12/02/2003	Methods For Generating Hypermutable Yeast
MORR-004-C1US	United States	11/188,743 7,514,216	07/26/2005 04/07/2009	Methods For Generating Hypermutable Yeast
MORR-004-C2US	United States	11/930,400 7,759,121	10/31/2007 07/20/2010	Methods For Generating Hypermutable Yeast
MORR-004-D1US	United States	10/641,068 6,921,666	08/15/2003 07/26/2005	Methods For Generating Hypermutable Yeast
MORR-004-U1CA	Canada	2399191	02/21/2001	Methods For Generating Hypermutable Yeast
MORR-004-U1EP	European Patent Convention	01911013.9 1259628	02/21/2001 01/17/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1AT	Austria	1259628	01/17/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1BE	Belgium	1259628	01/17/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1DK	Denmark	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1DE	Germany	1259628	01/07/2007	Methods For Generating Hypermutable Yeast

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-004-U1FI	Finland	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1FR	France	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1GB	United Kingdom	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1IT	Italy	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1NL	Netherlands	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1SE	Sweden	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-004-U1CH	Switzerland	1259628	01/07/2007	Methods For Generating Hypermutable Yeast
MORR-005-P2US	United States	60/203,905	05/12/2000	Method For Generating Hypermutable Organisms
MORR-005-P3US	United States	60/204,769	05/17/2000	Method For Generating Hypermutable Organisms
MORR-005-U2PC	Patent Cooperation Treaty	PCT/US2001/015376	05/14/2001	Method For Generating Hypermutable Organisms
MORR-005-U2US	United States	09/853,646 6,825,038	05/14/2001 11/30/2004	Method For Generating Hypermutable Organisms
MORR-005-C2US	United States	11/976,019	10/19/2007	Method for Generating Hypermutable Yeast
MORR-005-D2US	United States	10/873,114 7,319,036	06/23/2004 01/15/2003	Method For Generating Hypermutable Organisms
MORR-005-U2CA	Canada	2408826 2408826	05/14/2001 08/14/2012	Method For Generating Hypermutable Organisms
MORR-005-U2EP	European Patent Convention	01935403.4 1430123	05/14/2001 01/03/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2DE	Germany	1430123	01/03/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2FR	France	1430123	01/03/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2GB	United Kingdom	1430123	01/03/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2IT	Italy	1430123	01/08/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2NL	Netherlands	1430123	01/08/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2ES	Spain	1430123	01/08/2008	A Method For Generating Hypermutable Organisms

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-005-U2SE	Sweden	1430123	01/08/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2CH	Switzerland	1430123	01/08/2008	A Method For Generating Hypermutable Organisms
MORR-005-U2JP	Japan	2001-584574 5157036	05/14/2001 12/21/2012	Method For Generating Hypermutable Organisms
MORR-005-U2JP	Japan	2012-193802	05/14/2001	Method For Generating Hypermutable Organisms
MORR-006-U1PC	Patent Cooperation Treaty	PCT/US2001/000934	01/15/2001	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1US	United States	09/760,285 6,982,169	01/15/2001 01/03/2006	Chemical Inhibitors Of Mismatch Repair
MORR-006-D1US	United States	11/183,294 8,105,836	07/15/2005 01/31/2012	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1CA	Canada	2434926 2434926	01/15/2001 04/01/2014	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1EP	European Patent Convention	01901992.6 1351565	01/15/2001 03/16/2011	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1FR	France	1351565	03/16/2011	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1DE	Germany	60144247.4 1351565	03/16/2011	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1GB	United Kingdom	1351565	03/16/2011	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1CH	Switzerland	1351565	03/16/2011	Chemical Inhibitors Of Mismatch Repair
MORR-006-U1JP	Japan	2002-555609 5036119	01/15/2001 07/13/2012	Chemical Inhibitors Of Mismatch Repair
MORR-010-P1US	United States	60/500,071	09/03/2003	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-010-U1PC	Patent Cooperation Treaty	PCT/US2004/028905	09/03/2004	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-010-U1US	United States	10/933,034 7,604,994	09/02/2004 10/20/2009	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-010-D1US	United States	12/566,167	09/24/2009	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-010-U1AU	Australia	2004270714	09/03/2004	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-010-U1CA	Canada	2537881	09/03/2004	Antibody-Producing Cell Lines Expressing Activation-Induced-Cytidine-Deaminase And A Dominant Negative Allele Of A Mismatch Repair Gene
MORR-010-U1EP	European Patent Convention	04783230.8	09/03/2004	Antibody-Producing Cell Lines Expressing Activation-Induced-Cytidine-Deaminase And A Dominant Negative Allele Of A Mismatch Repair Gene
MORR-010-U1JP	Japan	2006-525489	09/03/2004	Genetically Altered Antibody-Producing Cell Lines With Improved Antibody Characteristics
MORR-011-U1PC	Patent Cooperation Treaty	PCT/US2000/030587	11/07/2000	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1US	United States	09/708,200 6,576,468	11/07/2000 06/10/2003	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-C1US	United States	10/369,845	02/19/2003	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-D1US	United States	11/235,037 7,223,598	09/26/2005 05/27/2007	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-D2US	United States	11/736,888 7,939,324	04/18/2007 05/10/2011	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1CA	Canada	2428158 2428158	11/07/2000 06/29/2010	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1EP	European Patent Convention	00977013.2 1343879	11/07/2000 01/08/2014	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1FR	France	1343879	01/08/2014	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1DE	Germany	60048399.1 1343879	11/07/2000 01/08/2014	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1GB	United Kingdom	1343879	01/08/2014	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1CH	Switzerland	1343879	01/08/2014	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells
MORR-011-U1JP	Japan	2002/542066	11/07/2000	Methods For Isolating Novel Antimicrobial Agents From Hypermutable Mammalian Cells

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-012-U1PC	Patent Cooperation Treaty	PCT/US2000/031135	11/14/2000	A Method For Generating Genetically Altered Antigens
MORR-012-U1US	United States	09/712,691 6,737,268	11/14/2000 05/18/2004	Method For Generating Genetically Altered Antigens
MORR-012-C1US	United States	10/813,502	03/30/2004	Method For Generating Genetically Altered Antigens
MORR-012-U1CA	Canada	2429134 2429134	11/14/2000 03/15/2011	A Method For Generating Genetically Altered Antigens
MORR-012-U1EP	European Patent Convention	00978578.3 1363930	11/14/2000 08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1BE	Belgium	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1CH	Switzerland	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1DE	Germany	60030172.9 1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1DK	Denmark	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1FI	Finland	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1FR	France	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1GB	United Kingdom	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1IT	Italy	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1NL	Netherlands	1363930	08/16/2006	A Method For Generating Genetically Altered Antigens
MORR-012-U1SE	Sweden	1363930	08/16/2016	A Method For Generating Genetically Altered Antigens
MORR-012-U1JP	Japan	543507/02	11/14/2000	A Method For Generating Genetically Altered Antigens
MORR-015-P1US	United States	60/349,565	01/18/2002	A Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1PC	Patent Cooperation Treaty	PCT/US2003/001361	01/17/2003	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1US	United States	10/348,074 7,638,334	01/17/2003 12/29/2009	Method For Generating Engineered Cells By Homologously Recombining Segments Having Increased Degeneracy

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-015-U1AU	Australia	2003205173 2003205173	01/17/2003 01/15/2009	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1CA	Canada	2473741 2473741	01/17/2003 12/22/2005	A Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1EP	European Patent Convention	03703842.9 1474522	01/17/2003 03/07/2012	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1CH	Switzerland	1474522	03/07/2012	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1DE	Germany	60340194.5 1474522	03/07/2012	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1FR	France	1474522	03/07/2012	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-015-U1GB	United Kingdom	1474522	03/07/2012	Method For Generating Engineered Cells For Locus Specific Gene Regulation And Analysis
MORR-016-P1US	United States	60/427,165	11/15/2002	Method For Generating High Titers Of Antibodies From In Vitro Immunized Cells
MORR-016-P2US	United States	60/501,650	09/10/2003	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1PCT	Patent Cooperation Treaty	PCT/US2003/036702	11/14/2003	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1US	United States	10/714,228 7,754,450	11/14/2003 07/13/2010	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1US	United States	12/786,530 8,445,229	05/25/2010 05/21/2013	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1AU	Australia	2003295576 2003295576	11/14/2003 06/30/2011	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1CA	Canada	2506127 2506127	11/14/2003 07/09/2013	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1EP	European Patent Convention	03786774.4 1572971	11/14/2003 09/30/2009	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1CH	Switzerland	1572971	09/30/2009	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-016-U1DE	Germany	60329526.6 1572971	09/30/2009	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1FR	France	157921	09/30/2009	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1GB	United Kingdom	157921	09/30/2009	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-016-U1JP	Japan	2004-570421 4555089	11/14/2003 07/23/2010	Methods For Generating High Production Of Antibodies From Hybridomas Created By In Vitro Immunizations
MORR-017-P1US	United States	60/491,310	07/29/2003	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1PC	Patent Cooperation Treaty	PCT/US2004/024436	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1US	United States	10/901,650	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-C1US	United States	12/251,889 7,807,416	10/15/2008 10/05/2010	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1AU	Australia	2004261229	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1CA	Canada	2534077	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1EP	European Patent Convention	04779481.3	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-017-U1JP	Japan	2006-522049	07/29/2004	Antibodies And Methods For Generating Genetically Altered Antibodies With Enhanced Effector Function
MORR-021-P1US	United States	60/528,269	12/08/2003	Antibodies That Specifically Bind PMS
MORR-021-U1PC	Patent Cooperation Treaty	PCT/US2004/041260	12/08/2004	Antibodies That Specifically Bind PMS
MORR-021-U1US	United States	11/007,428 7,332,584	12/08/2004 02/19/2008	Antibodies That Specifically Bind PMS
MORR-021-D1US	United States	11/962,295	12/21/2007	Antibodies That Specifically Bind PMS
MORR-021-U1AU	Australia	2004297265	12/08/2004	Antibodies That Specifically Bind PMS

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-021-U1CA	Canada	2548813	12/08/2004	Antibodies That Specifically Bind PMS
MORR-021-U1EP	European Patent Convention	04813570.1	12/08/2004	Antibodies That Specifically Bind PMS
MORR-021-U1AT	Austria	04813570.1	12/08/2004	Antibodies That Specifically Bind PMS
MORR-021-U1JP	Japan	2006-543981	12/08/2004	Antibodies That Specifically Bind PMS
MORR-022-P1US	United States	60/883,271	01/03/2007	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-P2US	United States	60/888,405	02/06/2007	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin
MORR-022-U1PC	Patent Cooperation Treaty	PCT/US2008/000104	01/03/2008	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1US	United States	11/969,097 8,236,932	01/03/2008 08/07/2012	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-C1US	United States	13/943,060 8,895,704	07/16/2013 11/25/2014	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D1US	United States	13/540,330 8,889,846	07/02/2012 11/18/2014	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D2US	United States	14/515,146 9,359,428	10/15/2014 06/07/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D3US	United States	15/144,334 9,868,780	05/02/2016 01/16/2018	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D4US	United States	15/839,403	12/12/2017	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B.
MORR-022-U1AU	Australia	2008205376 2008205376	01/03/2008 10/25/2012	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D1AU	Australia	2012241059 2012241059	01/03/2008 02/26/2015	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1CA	Canada	2,674,382 2,674,382	01/03/2008 05/31/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D1CA	Canada	2,924,155	01/03/2008	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B.
MORR-022-U1EP	European Patent Convention	08712978.9 2109622	01/03/2008 11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1BE	Belgium	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1DK	Denmark	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1FR	France	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1DE	Germany	602008047264.7 2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1IT	Italy	50201700012219 2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-022-U1NL	Netherlands	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1PL	Poland	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1ES	Spain	2619943 2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1SE	Sweden	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1CH	Switzerland	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-U1TR	Turkey	2109622	11/09/2016	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D1EP	European Patent Convention	16192106.9	01/03/2008	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B.
MORR-022-U1JP	Japan	2009-544928 5412293	01/03/2008 11/15/2013	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D1JP	Japan	2013-126119	01/03/2008	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-022-D2JP	Japan	2016-017809 6195946	02/02/2016 08/25/2017	High Affinity Antibodies That Neutralize Staphylococcus Enterotoxin B
MORR-028-P1US	United States	60/674,344	04/22/2005	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1PC	Patent Cooperation Treaty	PCT/US2006/015724	04/24/2006	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1US	United States	11/410,472 7,615,372	04/24/2006 11/10/2009	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-C1US	United States	13/685,231 8,524,237	11/26/2012 09/03/2013	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-D1US	United States	12/570,334 8,389,691	09/30/2009 03/05/2013	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1AU	Australia	2006241235 2006241235	04/24/2006 07/19/2012	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1CA	Canada	2,607,455	04/24/2006	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1EP	European Patent Convention	06769889.4	04/24/2006	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-028-U1JP	Japan	2008-508001	04/24/2006	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-028-D1JP	Japan	2011-290448	12/29/2011	Antibodies With Immune Effector Activity And That Internalize In Endosialian-Positive Cells
MORR-029-P1US	United States	60/910,362	04/05/2007	Methods For Inhibiting The Binding Of Inhibitors OF Endosialin to Ligands
MORR-029-P2US	United States	60/980,026	10/15/2007	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1PC	Patent Cooperation Treaty	PCT/US2008/059374	04/04/2008	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1US	United States	12/062,630 7,807,382	04/04/2008 10/05/2010	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-C1US	United States	14/509,353 9,505,842	10/08/2014 11/26/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-C2US	United States	15/295,177	10/17/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1US	United States	12/873,667 8,895,000	09/01/2010 11/25/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1AU	Australia	2008237296 2008237296	04/04/2008 10/17/2013	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1BR	Brazil	PI0809665-1	04/04/2008	Monoclonal Antibody Or Antigen-Binding Fragment
MORR-029-U1CA	Canada	2,682,726 2,682,726	04/04/2008 05/07/2017	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1CN	China	200880011474.9 ZL200880011474.9	04/08/2008 06/18/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1EP	European Patent Convention	08733125.2 2137217	04/04/2008 03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1AL	Albania	AL/P/2014/000062 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1AT	Austria	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1BE	Belgium	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1BA	Bosnia and Herzegovina	E01382 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1BG	Bulgaria	11177 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1HR	Croatia	P20140266 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1CY	Cyprus	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1CZ	Czech Republic	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1DK	Denmark	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-029-U1EE	Estonia	E009165 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1FI	Finland	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1FR	France	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1DE	Germany	602008030601.1 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1GB	United Kingdom	08733125.2 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1GR	Greece	3082954 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1HU	Hungary	E021557 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1IS	Iceland	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1IE	Ireland	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1IT	Italy	21180/BE/2014 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1LT	Lithuania	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1LI	Liechtenstein	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1LU	Luxembourg	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1MK	Republic of Macedonia	MK/P/2014/150 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1MT	Malta	08733125.2 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1MC	Monaco	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1NL	Netherlands	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1NO	Norway	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1PL	Poland	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1PT	Portugal	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1RO	Romania	EP/00425/2014 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1RS	Serbia	P-299/14 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1SK	Slovakia	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-029-U1SI	Slovenia	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1ES	Spain	ES2452929 T3 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1SE	Sweden	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1CH	Switzerland	2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1TR	Turkey	TR201403851T4 2137217	03/05/2014	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1EP	European Patent Convention	13162773.9 2620451	04/04/2008 09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1AL	Albania	AL/P/2016/00695 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1AT	Austria	E828887 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1BE	Belgium	13162773.9 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1BA	Bosnia and Herzegovina	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1BG	Bulgaria	16058/141116 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1HR	Croatia	P 20161715 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1CY	Cyprus	CY1118592 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1CZ	Czech Republic	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1DK	Denmark	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1EE	Estonia	E012869 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1FI	Finland	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1FR	France	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1DE	Germany	602008046353.2 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1GB	United Kingdom	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1GR	Greece	3090874 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1HU	Hungary	E031269 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1IS	Iceland	13162773.9 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-029-D1IE	Ireland	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1IT	Italy	502016000125210 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1LT	Lithuania	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1LI	Liechtenstein	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1LU	Luxembourg	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1MK	Republic of Macedonia	MK/P/2016/826 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1MT	Malta	13162773.9 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1MC	Monaco	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1NL	Netherlands	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1NO	Norway	13162773.9 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1PL	Poland	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1PT	Portugal	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1RO	Romania	EP/02049/2016 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1RS	Serbia	P-1097/16 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1SK	Slovakia	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1SI	Slovenia	13162773.9 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1ES	Spain	2606906 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1SE	Sweden	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1CH	Switzerland	2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1TR	Turkey	TR201615999T4 2620451	09/14/2016	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1JP	Japan	2010-502317 5825784	04/04/2008 10/23/2015	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1JP	Japan	2013-041304	03/01/2013	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-U1KR	South Korea	10-2009-7023061 10-1529334	04/04/2008 06/10/2015	Methods For Inhibiting The Binding of Endosialin To Ligands

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-029-U1MX	Mexico	MX/a/2009/010701 313234	04/04/2008 09/12/2013	Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-029-D1MX	Mexico	MX/a/2013/003514 323108	03/26/2013 08/27/2014	Methods For Inhibiting The Binding of Endosialin To Ligands Methods For Inhibiting The Binding of Endosialin To Ligands
MORR-032-P1US	United States	60/771,251	02/08/2006	Antigenic GM-CSF Peptides And Uses Thereof
MORR-032-P2US	United States	60/774,500	02/17/2016	Methods For Producing An Anti-GM-CSF Antibody
MORR-032-U1PC	Patent Cooperation Treaty	PCT/US2007/061874	02/08/2007	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1US	United States	11/672,902 7,741,450	02/08/2007 06/22/2010	Antibodies to GM-CSF
MORR-032-C1US	United States	13/659,165 8,623,364	10/24/2012 01/07/2014	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-C2US	United States	14/091,028 9,422,367	11/26/2013 08/23/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D1US	United States	12/761,464 8,318,168	04/16/2010 11/27/2012	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D2US	United States	15/212,779	07/18/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1AU	Australia	2007213716 2007213716	02/08/2007 03/25/2013	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D1AU	Australia	2013201228 2013201228	03/04/2013 05/05/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1CA	Canada	2,641,169 2,641,169	02/08/2007 05/07/2017	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D1CA	Canada	2,961,031	02/08/2007	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1CN	China	200780004846.0 ZL200780004846.0	02/08/2007 12/25/2013	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1EP	European Patent Convention	07763514.2 1981909	02/08/2007 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1AL	Albania	AL/P/2017/000023 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1AT	Austria	E836431 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1BE	Belgium	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1BA	Bosnia and Herzegovina	E02267 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1BG	Bulgaria	16361/291216 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-032-U1HR	Croatia	P20140024 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1CY	Cyprus	CY1118709 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1CZ	Czech Republic	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1DK	Denmark	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1EE	Estonia	E013225 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1FI	Finland	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1FR	France	07763514.2 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1DE	Germany	602007048297.6 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-32-U1GB	United Kingdom	07763514.2 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1GR	Greece	3091175 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1HU	Hungary	E032584 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1IS	Iceland	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1IE	Ireland	7763514.2 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1IT	Italy	502017000000838 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1LV	Latvia	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1LT	Lithuania	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1LU	Luxembourg	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1MK	Republic of Macedonia	P907176 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1MC	Monaco	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1NL	Netherlands	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1PL	Poland	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1PT	Portugal	1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1RO	Romania	EP/02258/2016 1981909	10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-032-U1RS	Serbia	55526 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1SK	Slovakia	 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1SI	Slovenia	 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1ES	Spain	2609088 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1SE	Sweden	 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1CH	Switzerland	 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1TR	Turkey	TR201619627 T4 1981909	 10/12/2016	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D1EP	European Patent Convention	16192629.0	02/08/2007	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1IN	India	3646/KOLNP/2008 292804	02/08/2007 01/24/2018	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1IL	Israel	193011 193011	02/08/2007 10/01/2015	An Antibody Binding Granulocyte Macrophage Colony Stimulating Factor, A Composition Comprising the Antibody, A Polynucleotide Encoding the Antibody, A Vector, A Cell and a Method for Preparing the Antibody
MORR-032-D1IL	Israel	235050 235050	10/07/2014 07/01/2017	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1JP	Japan	2008-554507 5210889	02/08/2007 03/01/2013	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-U1KR	South Korea	10-2008-7021791 10-1395515	02/08/2007 05/08/2014	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-032-D1KR	South Korea	10-2013-7029090 10/1486183	11/01/2013 01/19/2015	Antigenic GM-CSF Peptides And Antibodies To GM-CSF
MORR-043-P1US	United States	61/793,565	03/15/2013	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-U1PC	Patent Cooperation Treaty	PCT/US2014/029898	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-U1US	United States	14/770,840 9,915,660	08/27/2015 03/13/2018	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-D1US	United States	15/876,732	01/22/2018	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-U1BR	Brazil	BR1120150220851	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-U1EP	European Patent Convention	14762325.0	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer
MORR-043-U1JP	Japan	2016-503275	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer

Morphotek to Eisai, Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-043-U1MX	Mexico	MX/a/2015/013172	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer
~~MORR-038-P1US~~	~~United States~~	~~62/564,154~~	~~09/27/2017~~	~~Methods For Treating Mesothelin Expressing Cancer~~

SS 3 July 2018

Morphotek to Eisai, Inc.

Eisai Reference	Country	Application No. Patent No.	Filing Date Grant Date	Title
MORR-043-U1MX	Mexico	MX/a/2015/013172	03/15/2014	Methods For Determining Prognosis Of Colorectal Cancer
~~MORR-038-P1US~~	~~United States~~ MAB 4 Jun 2018	~~62/584,134~~	~~09/27/2017~~	~~Methods For Treating Mesothelin Expressing Cancer~~